Lucid Diagnostics (LUCD) Net Income towards Common Stockholders (2020 - 2026)
Lucid Diagnostics (LUCD) posted Net Income towards Common Stockholders of -$23.6 million for Q1 2026, down 44.79% on a QoQ basis from -$16.3 million in Q4 2025, and up 34.48% year-over-year from -$17.5 million in Q1 2025.
Lucid Diagnostics (LUCD) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Lucid Diagnostics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$23.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 34.48% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.2 million (up 17.97% YoY) and the FY2025 annual result came in at -$70.6 million, down 33.14% from the prior year.
- Net Income towards Common Stockholders was -$23.6 million for Q1 2026 at Lucid Diagnostics, down from -$16.3 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$7.9 million in Q2 2025 and bottomed at -$36.0 million in Q1 2025.
- A 5-year average of -$15.1 million and a median of -$14.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 235.89% — and 2026, when it jumped 34.48%.
- Lucid Diagnostics' Net Income towards Common Stockholders stood at -$14.9 million in 2022, then advanced by 27.45% to -$10.8 million in 2023, then dropped by 6.57% to -$11.5 million in 2024, then plunged by 41.24% to -$16.3 million in 2025, then sank by 44.79% to -$23.6 million in 2026.
- Business Quant data shows LUCD's Net Income towards Common Stockholders at -$23.6 million in Q1 2026, -$16.3 million in Q4 2025, and -$10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Lucid Diagnostics | 126.55 Mn | 98.67 Mn | -325,000.00 | -23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2025 | -16.30 Mn |
| Sep 30, 2025 | -10.40 Mn |
| Jun 30, 2025 | -7.89 Mn |
| Mar 31, 2025 | -36.02 Mn |
| Dec 31, 2024 | -11.54 Mn |
| Sep 30, 2024 | -12.37 Mn |
| Jun 30, 2024 | -11.01 Mn |
| Mar 31, 2024 | -18.11 Mn |
| Dec 31, 2023 | -10.83 Mn |
| Sep 30, 2023 | -14.21 Mn |
| Jun 30, 2023 | -11.38 Mn |
| Mar 31, 2023 | -16.25 Mn |
| Dec 31, 2022 | -14.93 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -14.62 Mn |
| Mar 31, 2022 | -12.27 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -6.96 Mn |
| Jun 30, 2021 | -6.16 Mn |